New startup ideas · Health and bio · Healthcare and bio

startup idea

Plasmidrun

GMP plasmid and mRNA batches ordered by API, no CDMO negotiation.

Plasmidrun runs small automated GMP suites and exposes them as an API: a small biotech posts a sequence, a batch size and a target release date, and gets back a scheduled slot, a price and, weeks later, a released batch with its full electronic batch record.

Infrastructure and APIs
Small business
$10-100B market
Platform others build on
Global from day one

4/5

venture judge

similar startups, last 2 years (1 all-time)

97%

of 4 nearest real companies still alive

yes

3 matching federal grants and programs

Direction supported by government programs and grants

Test it before you build it

$1,000 · 4 weeks · 25 prospects

Prove that seed-stage biotech founders will prepay $500 to reserve fixed-price one-week plasmid slots ordered through an API and sign dated GMP LOIs, for $1,000 in four weeks.

Riskiest assumption · A seed-stage founder who already buys research-grade plasmid by email will prepay a deposit to move that exact order to an unproven automated supplier for a fixed price and a one-week turnaround, rather than staying with Aldevron or GenScript because switching material suppliers feels riskier than waiting.

1Focus group: who and where

Founder or head of research at a 2-15 person US vaccine, cell or gene therapy company, pre-IND, who ordered research-grade plasmid from Aldevron, GenScript or VectorBuilder in the last six months and waited 4+ weeks past an emailed quote

where to find 25 · Resident company rosters at LabCentral in Cambridge and the BioLabs network sites; the Nucleate community of bio founders and its alumni chapters; SynBioBeta conference speaker and startup lists; r/biotech and r/labrats threads where founders compare plasmid vendors and lead times

2Sell first, build later

A research-grade plasmid run at a published fixed price with one-week turnaround from sequence submission, ordered through the API, first slots opening in 90 days; and for IND-bound teams, a GMP batch commitment at a published price band once the suite qualifies

the ask · $6,500 per research-grade run, flat, no quote cycle; $500 refundable deposit per reserved slot; GMP batch price band stated in the LOI

a real yes · A real yes is $500 landed by ACH with a signed reservation, a real sequence submitted through the docs page, or a CEO-signed LOI with a dated start window. Not a yes: 'ping us when you're live', unpaid letters of interest, or API keys requested and never used

3Small experiments

The first one attacks the riskiest assumption; each ends with a number that says whether to run the next.

1. Fifteen founder pitch calls
$700 · 14 days
Build a list of 25 named founders from LabCentral and BioLabs rosters, Nucleate, and SynBioBeta startup lists; one day trip to Cambridge for in-person meetings. On each call, pull up their last plasmid purchase order, show the published price sheet and mock API, and end with one ask: $500 refundable deposit to reserve a fixed-price slot in the first 90-day window.
keep going if · 6 of 15 confirm their last order took 4+ weeks from quote to material, and 5 of 15 agree to the reservation on the call
2. API docs fake door
$200 · 10 days
Publish real-looking API documentation: POST a sequence, batch size and target date, get back price and slot. The submit button requests an API key and takes a sequence file; nothing runs yet and the page says first slots open in 90 days. Send it to all 25 prospects and post once in Nucleate and r/labrats.
keep going if · 10 API key requests and 5 real sequence submissions from the 25 targeted teams
3. Collect slot deposits
$100 · 10 days
Invoice everyone who said yes: $500 refundable, reserving a research-grade run at the published fixed price with one-week turnaround once slots open. Money by ACH against a half-page reservation agreement the founder signs directly, no procurement.
keep going if · 4 paid $500 deposits within 10 days of the invoice going out
4. GMP LOI for IND-bound teams
$0 · 14 days
For the subset within 12 months of IND, send a two-page LOI: named molecule, GMP batch at a published price band, a dated start window contingent on suite qualification, signed by their CEO. This tests whether the research-to-GMP upgrade path is real demand, not a slide.
keep going if · 2 signed LOIs with a dated start window

4Collect a deposit up front

Tesla took $1,000 refundable reservations for the Model 3 and $100 for the Cybertruck before building either: the deposit is the measurement, not the revenue.

$500

per prospect, refundable

how · A refundable slot reservation invoiced at $500 by ACH against a half-page agreement the founder signs personally, sized at roughly 5-8 percent of the $6,500 run so a seed-stage founder can approve it without a board conversation; GMP commitments are taken as signed LOIs with dated start windows, not money, until the suite is qualified set up: Stripe Invoicing ↗

what it reserves · A slot in the first 90-day production window, the $6,500 flat price locked for the first three runs, and first access to the API when it goes live

refund · Refunded in full on request any time before the reserved slot's scheduled start date

target · 4 paid $500 deposits and 2 signed GMP LOIs from 15 calls within 30 days

before taking money · Take money only for research-use-only material: do not market, invoice or promise GMP or clinical-grade batches before the suite is qualified and released under cGMP, and keep all GMP demand as LOIs reviewed by counsel.

Go: build it if

4+ paid deposits from 15 pitched founders, 5+ real sequence submissions through the docs page, and 2 signed GMP LOIs with dated start windows

Kill: stop if

0-1 deposits after 15 calls and 5 sent invoices, or founders consistently saying they will stay with Aldevron or GenScript because material risk outweighs a month of waiting

5 Scripts to run itoutreach message, landing copy, deposit terms · click to open

outreach message

If your last plasmid order went the usual way, you emailed for a quote, waited a week for a price, then a month for material. I'm building automated production suites you order from like an API: post a sequence, get a slot, price and date back, material in a week. First slots open in 90 days at a flat $6,500 per research-grade run, and I'm reserving them now with $500 refundable deposits. Can I get 20 minutes this week to walk through your last order against our price sheet?

landing page

Clinical-grade plasmid ordered like an API call, not a negotiation. $6,500 flat per research-grade run, one-week turnaround; $500 refundable deposit reserves a slot in the first 90-day window. Post your sequence and reserve a slot.

deposit terms

Your $500 deposit reserves one research-grade production slot in our first 90-day window and locks the $6,500 flat price for your first three runs. It is fully refundable on request any time before your slot's scheduled start date. Research use only; GMP batches are committed separately by LOI once our suite completes qualification.

Would you run this test?

One tap. The yes-share feeds the Demand pillar of this idea's score; nobody sees who answered.

Budgets are out-of-pocket estimates for a team of one to three, US market. Size the deposit to the deal, and check the terms before taking money in a regulated line.

Scorecard

One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.

Idea Score, 0-100 · raw 52.4 x 1.61

Open

competition: more crowded than 6% of ideas · headwind x0.97

+0.8

government priorities, secondary (1 matching grants)

Trend

Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.

Entrants 2025-26 vs 2023-24 (similar companies)23
Rounds announced 2025+ in the sector69
Sector direction (live batch)100
2026 trend analyst25

Demand

Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.

YC asks for it (current RFS: idea / sector)30
Someone already pays (similar companies, recent / all-time)8
Operator judge: real pain75
Founders' yes-rate in decks27

100x potential

Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.

Venture judge75
Market size axis67
Moat axis80
Technologist judge100

Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were gmp, plasmid, mrna, batches, ordered, cdmo, negotiation, automated.

The idea in full

What: Plasmidrun runs small automated GMP suites and exposes them as an API: a small biotech posts a sequence, a batch size and a target release date, and gets back a scheduled slot, a price and, weeks later, a released batch with its full electronic batch record. Closed-loop process control models trained on every run set the parameters, which is what lets a two-person team order clinical-grade material without a tech transfer project. The build is capital-heavy, the regulatory burden is full cGMP, and first revenue comes from research-grade runs in year one while the GMP suite qualifies.
Why now: The radar shows the demand side collapsing to tiny teams that still need real material: Omanta (yc S26) is literally a research lab for one, TareBio (yc S26) promises vaccines for any cancer or infection in weeks, and AbInitio Bio (yc X26) is building an intelligence layer for drug manufacturing, while Ambrosia Biosciences raised a $100M Series B on 2026-03-31, so capital exists for the physical layer.
Wedge: first customer and entry point: Seed-stage vaccine and cell therapy teams buying research-grade plasmid today by email: same molecule, same API, one week turnaround, then upgrade them to the GMP slot when they hit IND.
Path to 100x: Biologics contract manufacturing is a $10 to 100B market that is priced and scheduled for large pharma, so small teams wait months and overpay. The distribution moat is being the default execute button inside the design tools and AI protein and sequence platforms those teams already use, so every new design tool that ships a Plasmidrun endpoint routes its users' first clinical material here, and the process-control model gets better with each batch.
Ceiling: Suite capacity is physical, so growth is gated by capex per additional site and a competitor with cheaper capital can copy the API without copying anything hard.
Closest real companies, as the generator saw them: AbInitio Bio sells software intelligence into other people's plants; Plasmidrun owns the plant and sells capacity as an endpoint. Omanta automates discovery-scale experiments, not clinical-grade batch release.
Main risk: GMP qualification and deviation handling swallow the automation advantage, and Plasmidrun ends up a normal CDMO with worse margins and a nicer website.

Five judges

Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).

Venture investor
4/5
Being the default execute button inside design tools is a distribution moat on a $10-100B market, though capex per suite gates growth.
Bootstrapper
1/5
Automated GMP suites under full cGMP are capex plus qualification years, far past what a two-person team can fund.
Operator
4/5
Seed biotechs already pay six figures and wait months for plasmid slots, and they order by email today, so the API replaces an existing invoice.
Technologist
5/5
Automated GMP suites with closed-loop process control trained on every run is cGMP hardware plus models that improve batch by batch.
Risk
3/5
Full cGMP footing is owned, but capacity sits in single suites and the distribution moat depends on third-party design tools shipping a Plasmidrun endpoint.
trends
2/5
GMP-by-API depends on no regulation or protocol dated 2025-2026; the cited $100M Series B funds a competitor's layer, not this window.

Similar startups in the directory

Companies whose pitch matches most of the idea's terms (gmp, plasmid, mrna, batches, ordered, cdmo, negotiation, automated): 1 all-time, 0 from the last two years. Same matching as Idea Check.

Flowspaceyc S17 · 2017 · Commerce and marketplacesalive
The operating system powering ecommerce fulfillment

Run this as an Idea Check →

The generator's reference companies

Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.

Public money in this direction

US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.

grants and programs matching the idea

1595

startup-relevant grants in Healthcare and bio

$854M

awarded in the sector, tracked

118

opportunities open now in the sector

Automated 2D Cell & Gene Therapy Manufacturing Platformawardhigh relevance
NIH / NIGMS · SBIR phase I · $221K · posted 2026-09-15
STING agonist-expressing BCG to enhance bladder cancer therapyawardmedium relevance
NIH / NCI · SBIR phase II · $1M · posted 2026-09-10
Rapid Control and Assessment of Dissolved Gas Signals on Tissue Function andDisease.awardmedium relevance
NIH / NIGMS · STTR phase I · $307K · posted 2025-09-04

All public money by sector →

Market signal

What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.

Healthcare and bio · 135 → 121 → 224 → 173 → 127 new companies 2022 → 2026 · 91% aliveYC F26 live: 2 in this cluster, 2% of the batch (was 6% in S26)Since February, of 442 YC companies here: 6 acquired, 6 shut down, 45 rewrote their pitch

Healthcare and bio: companies, trend and grants →

Design attributes

The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.

Buyer: Small business
Business model: Infrastructure and APIs
Path to 100x: Platform others build on
Market size: $10-100B market
Capital intensity: Capital-heavy (hardware, bio, infra)
Speed to revenue: Revenue in 1-3 years
Technical depth: Deep tech: ML, hardware, bio
Go-to-market: Self-serve
Moat: Distribution moat
Geography: Global from day one
Regulation: Heavily regulated
Vibe: Hot space